title: Pharmacological characterization of LY593093, an M1 muscarinic acetylcholine receptor-selective partial orthosteric agonist.
abstract: Alzheimer's disease and schizophrenia are characterized by expression of psychotic, affective, and cognitive symptoms. Currently, there is a lack of adequate treatment for the cognitive symptoms associated with these diseases. Cholinergic signaling and, in particular, M1 muscarinic acetylcholine receptor (m1AChR) signaling have been implicated in the regulation of multiple cognitive domains. Thus, the M1AChR has been identified as a therapeutic drug target for diseases, such as schizophrenia and Alzheimer's disease, that exhibit marked cognitive dysfunction as part of their clinical manifestation. Unfortunately, the development of selective M1 agonist medications has not been successful, mostly because of the highly conserved orthosteric acetylcholine binding site among the five muscarinic receptor subtypes. More recent efforts have focused on the development of allosteric M1AChR modulators that target regions of the receptor distinct from the orthosteric site that are less conserved between family members. However, orthosteric and allosteric ligands may differentially modulate receptor function and ultimately downstream signaling pathways. Thus, the need for highly selective M1AChR orthosteric agonists still exists, not only as a potential therapeutic but also as a pharmacological tool to better understand the physiologic consequences of M1AChR orthosteric activation. Here, we describe the novel, potent and selective M1AChR orthosteric partial agonist LY593093 [N-[(1R,2R)-6-({(1E)-1-[(4-fluorobenzyl)(methyl)amino]ethylidene})amino)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]biphenyl-4-carboxamide]. This compound demonstrates modest to no activity at the other muscarinic receptor subtypes, stimulates Gα(q)-coupled signaling events as well as β-arrestin recruitment, and displays significant efficacy in in vivo models of cognition.
authors.affiliation: Lilly Research Laboratories, Eli Lilly & Co., Lilly Corporate Center, Indianapolis, IN 46285, USA.
authors.forename: Marla L
authors.initials: ML
authors.lastname: Watt
authors.forename: Douglas A
authors.initials: DA
authors.lastname: Schober
authors.forename: Stephen
authors.initials: S
authors.lastname: Hitchcock
authors.forename: Bin
authors.initials: B
authors.lastname: Liu
authors.forename: Amy K
authors.initials: AK
authors.lastname: Chesterfield
authors.forename: David
authors.initials: D
authors.lastname: McKinzie
authors.forename: Christian C
authors.initials: CC
authors.lastname: Felder
mesh_terms: D000109:Acetylcholine / Q000378:metabolism; D000818:Animals; D001667:Binding, Competitive / Q000187:drug effects; D001713:Biphenyl Compounds / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology*; D016466:CHO Cells; D020013:Calcium Signaling / Q000187:drug effects; D003072:Cognition Disorders / Q000378:metabolism / Q000517:prevention & control; D006224:Cricetinae; D003412:Cricetulus; D004195:Disease Models, Animal; D054333:Drug Partial Agonism; D007192:Indenes / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology*; D051379:Mice; D018345:Mice, Knockout; D018721:Muscarinic Agonists / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D011485:Protein Binding / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D043643:Receptor, Muscarinic M1 / Q000819:agonists* / Q000378:metabolism
chemical_list: D001713:Biphenyl Compounds; D007192:Indenes; D018721:Muscarinic Agonists; C561313:N-(6-((1-((4-fluorobenzyl)(methyl)amino)ethylidene))amino)-2-hydroxy-2,3-dihydro-1H-inden-1-ylbiphenyl-4-carboxamide; D043643:Receptor, Muscarinic M1; D000109:Acetylcholine